Expand all sections

Eptacog beta (activated)

Extended indication Haemophilia A and B; in patients with inhibitory antibodies to factor VIII or IX.
Therapeutic value Possible equal value
Total cost 342,000.00
Registration phase Clinical trials

Product

Active substance Eptacog beta (activated)
Domain Cardiovascular diseases
Reason of inclusion New medicine (specialité)
Main indication Hemostasis promoting medication
Extended indication Haemophilia A and B; in patients with inhibitory antibodies to factor VIII or IX.
Manufacturer rEVO
Mechanism of action Coagulant
Therapeutical formulation Intravenous drip
Budgetting framework Intermural (MSZ)
Additional remarks Meer informatie over de werking van het product: "A transgenically produced recombinant form of human factor VIIa."

Registration

Registration route Centralised (EMA)
Submission date 2019
Expected Registration 2020
Orphan drug No
Registration phase Clinical trials

Therapeutic value

Current treatment options Eptacog alfa, emicizumab, protrombinecomplexen
Therapeutic value Possible equal value
Substantiation Het verschil tussen eptacog alfa is, in tegenstelling tot eptacog beta, geproduceerd op transgene wijze. Daardoor zou het een stabielere / natuurlijkere glycosylering hebben dan recombinant geproduceerd eptacog alfa. Echter klinische vergelijking tussen deze twee ontbreekt. Betreft grotendeels substitutie.
References NCT02548143
Additional remarks PERSEPT 1: "Intravenous 75 μg/kg or 225 μg/kg initial doses with 75 μg/kg subsequent doses by schedule were administered until clinical response."

Expected patient volume per year

Patient volume

< 30

Market share is generally not included unless otherwise stated.
References NVHB
Additional remarks Aantallen patiënten hemofilie A met remmers wordt door de behandelaren (NVHB) ingeschat op maximaal totaal 30 patiënten.

Expected cost per patient per year

Cost 5,700.00 - 17,100.00
References Medicijnkosten.nl
Additional remarks De verwachting is dat de prijs vergelijkbaar zal zijn met eptacog alfa (€820 voor een spuit van 1 mg). Per toediening zal er gemiddeld ongeveer 7 mg moeten worden toegediend (€5.700). Bij bloedingen 1-3 toedieningen (max €17.100), bij profylaxe meermaals.

Potential total cost per year

Total cost

342,000.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension No

Other information

There is currently no futher information available.